Markets

MediciNova' COVID-19 Vaccine Induces Systemic Serum IgG, Mucosal IgA Neutralizing Antibodies In Mice

(RTTNews) - MediciNova Inc.'s (MNOV) intranasal BC-PIV SARS-CoV-2 vaccine has successfully induced systemic serum IgG and mucosal IgA neutralizing antibodies against the S1 antigen (Ag) of SARS-CoV-2 in mice.

The SI protein of the virus is one of the key targets of COVID-19 vaccines. S1 contains a receptor-binding domain, allowing the virus to dock to body receptors, paving way for entry into cells and leading to infection.

The BC-PIV SARS-CoV-2 vaccine contains BC-PIV, an innovative non-transmissible viral vector derived from the recombinant human parainfluenza virus type 2 (hPIV2), and is co-developed by BioComo and Mie University. MediciNova has an agreement with BioComo and Mie University for joint development of the BC-PIV SARS-CoV-2 vaccine.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

MNOV

Latest Markets Videos

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Learn More